Table 2.
Parameter | Normal | Sham | SCI control | Methylprednisolone (30) | Fisetin (10) | Fisetin (20) | Fisetin (40) |
---|---|---|---|---|---|---|---|
TNF-α/β-actin ratio | 0.15 ± 0.03 | 0.33 ± 0.03 | 1.46 ± 0.02#,& | 0.38 ± 0.06*,$ | 1.37 ± 0.03 | 0.93 ± 0.02*,$ | 0.69 ± 0.05*,$ |
IL-1β/β-actin ratio | 0.51 ± 0.07 | 0.76 ± 0.08 | 2.16 ± 0.04#,& | 0.78 ± 0.06*,$ | 2.09 ± 0.08 | 1.56 ± 0.08*,$ | 1.02 ± 0.07*,$ |
IL-6/β-actin ratio | 0.67 ± 0.04 | 0.80 ± 0.03 | 1.49 ± 0.05#,& | 0.86 ± 0.06*,$ | 1.37 ± 0.02 | 1.02 ± 0.05*,$ | 0.92 ± 0.04*,$ |
iNOs/β-actin ratio | 0.44 ± 0.05 | 0.73 ± 0.09 | 2.07 ± 0.07#,& | 0.78 ± 0.06*,$ | 1.92 ± 0.08 | 1.39 ± 0.07*,$ | 0.94 ± 0.02*,$ |
COX-II/β-actin ratio | 0.15 ± 0.03 | 0.28 ± 0.02 | 1.06 ± 0.03#,& | 0.52 ± 0.05*,$ | 0.96 ± 0.04 | 0.75 ± 0.05*,$ | 0.54 ± 0.02*,$ |
BDNF/β-actin ratio | 1.03 ± 0.09 | 1.03 ± 0.02 | 0.28 ± 0.04#,& | 0.98 ± 0.06*,$ | 0.44 ± 0.06 | 0.71 ± 0.05*,$ | 0.91 ± 0.06*,$ |
Bax/β-actin ratio | 0.39 ± 0.06 | 0.45 ± 0.05 | 1.47 ± 0.07#,& | 0.61 ± 0.06*,$ | 1.35 ± 0.05 | 1.11 ± 0.07*,$ | 0.80 ± 0.05*,$ |
Bcl-2/β-actin ratio | 3.41 ± 0.07 | 3.08 ± 0.04 | 0.87 ± 0.09#,& | 2.94 ± 0.10*,$ | 1.36 ± 0.13 | 1.87 ± 0.16*,$ | 2.79 ± 0.08*,$ |
Caspase-3/β-actin ratio | 0.36 ± 0.03 | 0.41 ± 0.03 | 1.21 ± 0.02#,& | 0.60 ± 0.06*,$ | 1.06 ± 0.04 | 0.92 ± 0.05*,$ | 0.60 ± 0.03*,$ |
Data are expressed as mean ± SEM (n = 4) and one-way ANOVA followed by Tukey’s multiple range test.
ANOVA, analysis of variance; COX-II, cyclooxygenase-II; Bax, Bcl-2-associated X; Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; iNOS, inducible nitric oxide synthase; IL-1β, interleukin-1 beta; IL-6, interleukin-6; SCI, spinal cord injury; TNF-α, tumor necrosis factor-alpha.
#P < 0.05 as compared with sham group.
&P < 0.05 as compared with normal.
*P < 0.05 as compared with the SCI control group.
$P < 0.05 as compared with one another.